These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 33431338)

  • 1. N of 1 Data Sharing: The Impact of Data Sharing within the Hematology-Oncology Drug Products Division of the US FDA.
    Gill J; Prasad V
    Trends Cancer; 2021 May; 7(5):395-399. PubMed ID: 33431338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview of Oncology and Hematology Drug Approvals at US Food and Drug Administration Between 2008 and 2016.
    Zhou J; Vallejo J; Kluetz P; Pazdur R; Kim T; Keegan P; Farrell A; Beaver JA; Sridhara R
    J Natl Cancer Inst; 2019 May; 111(5):449-458. PubMed ID: 30085269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration.
    Modi ND; Abuhelwa AY; McKinnon RA; Boddy AV; Haseloff M; Wiese MD; Hoffmann TC; Perakslis ED; Rowland A; Sorich MJ; Hopkins AM
    JAMA Oncol; 2022 Sep; 8(9):1310-1316. PubMed ID: 35900732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-Reported Outcomes Labeling for Products Approved by the Office of Hematology and Oncology Products of the US Food and Drug Administration (2010-2014).
    Gnanasakthy A; DeMuro C; Clark M; Haydysch E; Ma E; Bonthapally V
    J Clin Oncol; 2016 Jun; 34(16):1928-34. PubMed ID: 27069082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Food and Drug Administration process for development and approval of drugs and radiopharmaceuticals: treatments in urologic oncology.
    Ning YM; Maher VE
    Urol Oncol; 2015 Mar; 33(3):137-42. PubMed ID: 25613202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Comparative Effectiveness of Innovative Treatments for Cancer (CEIT-Cancer) project: Rationale and design of the database and the collection of evidence available at approval of novel drugs.
    Ladanie A; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
    Trials; 2018 Sep; 19(1):505. PubMed ID: 30231912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics: A Review.
    Beaver JA; Howie LJ; Pelosof L; Kim T; Liu J; Goldberg KB; Sridhara R; Blumenthal GM; Farrell AT; Keegan P; Pazdur R; Kluetz PG
    JAMA Oncol; 2018 Jun; 4(6):849-856. PubMed ID: 29494733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Timing of first-in-child trials of FDA-approved oncology drugs.
    Neel DV; Shulman DS; DuBois SG
    Eur J Cancer; 2019 May; 112():49-56. PubMed ID: 30928805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
    Salcher-Konrad M; Naci H; Davis C
    Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years.
    Jacquet E; Kerouani-Lafaye G; Grude F; Goncalves S; Lorence A; Turcry F; Brunel L; Belgodere L; Monard A; Guyader G; Boudali L; Albin N
    Eur J Cancer; 2021 May; 149():82-90. PubMed ID: 33838392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and Regulatory Aspects of Companion Diagnostic Development in Oncology.
    Jørgensen JT; Hersom M
    Clin Pharmacol Ther; 2018 Jun; 103(6):999-1008. PubMed ID: 29197081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of Real-World Evidence to Support FDA Approval of Oncology Drugs.
    Feinberg BA; Gajra A; Zettler ME; Phillips TD; Phillips EG; Kish JK
    Value Health; 2020 Oct; 23(10):1358-1365. PubMed ID: 33032780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Drug-Dosing Conundrum in Oncology - When Less Is More.
    Shah M; Rahman A; Theoret MR; Pazdur R
    N Engl J Med; 2021 Oct; 385(16):1445-1447. PubMed ID: 34623789
    [No Abstract]   [Full Text] [Related]  

  • 14. Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration.
    Tibau A; Molto C; Ocana A; Templeton AJ; Del Carpio LP; Del Paggio JC; Barnadas A; Booth CM; Amir E
    J Natl Cancer Inst; 2018 May; 110(5):486-492. PubMed ID: 29244173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?
    Richey EA; Lyons EA; Nebeker JR; Shankaran V; McKoy JM; Luu TH; Nonzee N; Trifilio S; Sartor O; Benson AB; Carson KR; Edwards BJ; Gilchrist-Scott D; Kuzel TM; Raisch DW; Tallman MS; West DP; Hirschfeld S; Grillo-Lopez AJ; Bennett CL
    J Clin Oncol; 2009 Sep; 27(26):4398-405. PubMed ID: 19636013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.
    Ladanie A; Schmitt AM; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Herbrand AK; Briel M; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
    JAMA Netw Open; 2020 Nov; 3(11):e2024406. PubMed ID: 33170262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approved.
    Zhang SX; Fergusson D; Kimmelman J
    J Natl Cancer Inst; 2020 Sep; 112(9):886-892. PubMed ID: 32239146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A fresh perspective on comparing the FDA and the CHMP/EMA: approval of antineoplastic tyrosine kinase inhibitors.
    Shah RR; Roberts SA; Shah DR
    Br J Clin Pharmacol; 2013 Sep; 76(3):396-411. PubMed ID: 23362829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval.
    Parikh RB; Hubbard RA; Wang E; Royce TJ; Cohen AB; Clark AS; Mamtani R
    JAMA Oncol; 2023 Apr; 9(4):567-569. PubMed ID: 36821118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiologically Based Pharmacokinetic Modeling in Pediatric Oncology Drug Development.
    Rioux N; Waters NJ
    Drug Metab Dispos; 2016 Jul; 44(7):934-43. PubMed ID: 26936973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.